Oncocyte Overview
Oncocyte (OCX) has a P/E ratio of -2.72, below the Technology sector average of 27.19.
Get informed when a big investor buys or sells
+ Follow-2.72
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, OCX shows a P/E ratio of -2.72. That is below the Technology sector average of 27.19. Scroll down for historical charts and peer comparison views.
The Technology sector average P/E ratio is about 27.19. Oncocyte is at -2.72, which is lower that average. That is roughly 110.0% below the sector mean. Use the comparison chart on this page to see how OCX stacks up against individual peers as well.
Investors watch OCX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Oncocyte's latest reading is -2.72. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Oncocyte's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -2.72) with ownership activity and broader fundamentals.
The Technology average P/E ratio is about 27.19, while OCX is at -2.72. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
